Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX108 in advanced solid tumors
NCT03646071Phase 1Unknown
- Sponsor
- NeuPharma
- Start
- Aug 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RX108 in solid tumor (2 arms), sponsored by NeuPharma. Primary endpoints: Maximum Tolerated Dose and Incidence of Adverse Events and Serious Adverse Events. Status: unknown.
02
Drugs
RX108
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03646071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646071.